Afimetoran（Cat No.:I021476）is a potent, selective dual inhibitor of Toll-like receptors 7 and 8 (TLR7/8), key mediators of innate immune activation. By blocking these receptors, Afimetoran reduces the production of pro-inflammatory cytokines, offering therapeutic potential in autoimmune diseases such as systemic lupus erythematosus (SLE). Its targeted mechanism helps restore immune balance while minimizing broad immunosuppression. Afimetoran exhibits favorable pharmacokinetics and safety profiles in preclinical and early clinical studies, supporting its development as a novel immunomodulatory agent. It represents a promising strategy for treating chronic inflammation and autoimmunity.